title: Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide - A pilot study.
abstract: We examined the effects of liraglutide, a glucagon-like peptide-1 analogue on appetite and plasma ghrelin in non-diabetic obese participants with subclinical binge eating (BE). Forty-four obese BE participants (mean age: 34±9 years, BMI: 35.9±4.2kg/m(2)) were randomly assigned to intervention or control groups for 12 weeks. All participants received standard advice for diet and exercise. Binge eating score, ghrelin levels and other anthropometric variables were evaluated at baseline and at the end of the study. Participants who received liraglutide showed significant improvement in binge eating, accompanied by reduction in body weight, BMI, waist circumference, systolic blood pressure, fasting glucose and total cholesterol. Ghrelin levels were significantly increased which may potentially diminish the weight loss effects of liraglutide beyond the intervention.
authors: Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia. Electronic address: sarahrobert@ppukm.ukm.edu.my.
authors: Sarah Anne
authors: SA
authors: Robert
authors: Faculty of Medicine, Universiti Teknologi Mara, Sungai Buloh, Selangor, Malaysia.
authors: Abdul Ghani
authors: AG
authors: Rohana
authors: Department of Community Health, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
authors: Shamsul Azhar
authors: SA
authors: Shah
authors: Department of Social and Preventive Medicine, Faculty of Medicine Universiti Malaya, Kuala Lumpur, Malaysia.
authors: Karuthan
authors: K
authors: Chinna
authors: Cardiovascular, Diabetes and Nutrition Research Centre, Institute for Medical Research, Kuala Lumpur, Malaysia.
authors: Wan Nazaimoon
authors: WN
authors: Wan Mohamud
authors: Department of Medicine, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia.
authors: Nor Azmi
authors: NA
authors: Kamaruddin
mesh_terms: D000328:Adult; D001067:Appetite Depressants / Q000008:administration & dosage / Q000627:therapeutic use*; D056912:Binge-Eating Disorder / Q000503:physiopathology / Q000517:prevention & control*; D015992:Body Mass Index; D003131:Combined Modality Therapy; D004038:Diet, Reducing; D054439:Ghrelin / Q000097:blood; D052216:Glucagon-Like Peptide 1 / Q000819:agonists / Q000031:analogs & derivatives; D006801:Humans; D006963:Hyperphagia / Q000503:physiopathology / Q000517:prevention & control*; D054795:Incretins / Q000008:administration & dosage / Q000627:therapeutic use*; D007267:Injections; D000069450:Liraglutide / Q000008:administration & dosage / Q000627:therapeutic use*; D009043:Motor Activity; D009765:Obesity / Q000097:blood / Q000188:drug therapy* / Q000209:etiology / Q000523:psychology; D010865:Pilot Projects; D012720:Severity of Illness Index; D055105:Waist Circumference; D015431:Weight Loss
chemical_list: D001067:Appetite Depressants; C515349:GHRL protein, human; D054439:Ghrelin; D054795:Incretins; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1
keywords: Binge eating; Ghrelin; Glucagon-like peptide-1; Liraglutide; Obesity